Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Summarize this article with:
SA Transcripts157.29K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma December 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic AnalysisGeorge Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-ChairmanL. Sirulnik - Senior Vice President of Clinical Development Unit Head & HematologyKaren Rodriguez LorencJustin Holko Conference Call Participants Nicholas Lorusso - TD Cowen, Research DivisionAlexandria Hammond - Wolfe Research, LLCShrunatra Mishra - Goldman Sachs Group, Inc., Research DivisionMario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research DivisionConor MacKay - BMO Capital Markets Equity ResearchJohoon Kim - RBC Capital Markets, Research DivisionSimon Baker - Rothschild & Co Redburn, Research DivisionMohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Operator Welcome to the Regeneron conference call to discuss its Lynozyfic development program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin. Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis Thank you, Shannon. Good morning, and welcome to our Regeneron Roundtable Investor event, a series of presentations spotlighting key opportunities across our pipeline. Today, we will focus on our Lynozyfic development program in multiple myeloma and precursor conditions. Today's roundtable features key leaders from Regeneron, including Dr. George Yancopoulos, Board Co-Chair, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President and Clinical Development Unit Head, Hematology; Dr. Karen Rodriguez-Lorenc, Vice President of Malignant Hematology Therapeutic Area Leader; and Justin Holko, Senior Vice President, Oncology and Hematology Commercial. Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement Recommended For You